What Oxford BioTherapeutics does

Oxford BioTherapeutics (OBT) is a clinical-stage, privately held oncology company founded in 2004 and headquartered in Oxford, United Kingdom, with US operations in San Jose, California. The company develops first-in-class antibody-based cancer therapies across multiple modalities — antibody-drug conjugates (ADCs), T-cell engagers (TCEs), immuno-oncology antibodies, CAR-T cell therapies, and radiopharmaceuticals — and is supported by a stated headcount of 75+ employees. Its core technology is the proprietary OGAP-Verify proteomics platform, described as the world's largest cancer-specific membrane protein abundance database, containing data on approximately 7,000 membrane proteins across solid and hematological malignancies and normal tissues, generated using quantitative mass spectrometry directly on patient cancer biopsies with detection sensitivity down to 50 copies per cell. A complementary platform, OGAP-Splice, applies AI and machine learning to identify novel cell surface-expressed splice variants as a distinct class of antibody targets.

The company's pipeline is structured around strategic pharmaceutical partnerships rather than independent commercialization. Active collaborations include a long-standing relationship with Boehringer Ingelheim (initiated 2013, expanded 2020 and 2023) that has produced obrixtamig, a DLL3/CD3 T-cell engager now in global Phase 3 trials for extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinoma, as well as BI 3820768 (OB33), which entered clinical development in June 2026. In December 2025, OBT signed a multi-target antibody collaboration with GSK, and in April 2026 it signed a multi-year T-cell engager collaboration with Bristol Myers Squibb; a relationship with Roche is also active. Across these partnerships, the company has disclosed 4 partnered clinical assets, 13 partnered pre-clinical assets, and a total of approximately 170 partnered assets spanning 100+ novel cancer-specific targets.

Oxford BioTherapeutics generates revenue through licensing and royalty arrangements: partners fund and lead downstream research, development, and commercialization while OBT receives upfront payments, R&D and development milestones, and royalties on net sales. OBT is backed by a syndicate of institutional investors including Perscitus, ALSA Ventures, Kaitai Capital, Calculus Capital, Catapult Ventures, Oxford Capital, and Percipient Capital, and has raised approximately $32 million across disclosed equity and debt rounds since 2005, including a $10 million senior secured term loan from Oxford Finance in January 2024. The company is founder-led, with Christian Rohlff, PhD, serving as Chief Executive Officer.

Name

Oxford BioTherapeutics

Legal name

Oxford BioTherapeutics Limited

Website

https://oxfordbiotherapeutics.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Oxford BioTherapeutics is a clinical-stage UK oncology company that discovers first-in-class antibody-based cancer therapies (ADCs, T-cell engagers, immuno-oncology, CAR-T, radiopharmaceuticals) using its proprietary OGAP-Verify and OGAP-Splice proteomics platforms, commercializing exclusively through partnerships with major pharmaceutical companies such as Boehringer Ingelheim, Bristol Myers Squibb, GSK, and Roche.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics Discovery

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Proteomics & Mass Spectrometry Services (HLAGANAB)

Keywords

• Antibody-based cancer therapies
• Proteomics target discovery
• Oncology drug development
• Antibody-drug conjugates
• Pharmaceutical research partnerships

Headquarters

HQ city

Oxton

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Strategic Collaboration Payments: Oxford BioTherapeutics receives upfront payments, milestone payments, and royalties on net sales from strategic pharmaceutical partnerships. Partners lead subsequent research, development, and commercialization activities while OBT provides its OGAP-Verify platform for target discovery.
2. Debt Financing: Oxford Finance provided a $10 million senior secured term loan to support development of antibody-based cancer therapies targeting acute myeloid leukemia, breast cancer, and other solid cancers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Oxford BioTherapeutics is a clinical-stage oncology company that uses its proprietary OGAP-Verify and OGAP-Splice proteomics platforms to discover novel, cancer-specific membrane protein targets, then develops antibody-based therapeutics (ADCs, T-cell engagers, immuno-oncology antibodies, CAR-T, and radiopharmaceuticals) in collaboration with major pharmaceutical partners who fund and lead downstream development and commercialization. Revenue is generated through upfront payments, development milestones, and royalties on partnered assets.

Product overview

Oxford BioTherapeutics is a clinical-stage oncology company pioneering next-generation antibody-based cancer therapies through its proprietary OGAP®-Verify and OGAP®-Splice platforms. These platforms identify novel cancer-specific membrane proteins and splice variants to drive development of multiple therapeutic modalities including Antibody-Drug Conjugates (ADCs), T-cell Engagers (TCE), Immuno-oncology antibodies, CAR-T therapies, and radiopharmaceuticals. The company's pipeline includes partnered clinical programmes with Boehringer Ingelheim (obrixtamig/OBT620 in Phase 3, BI 3820768 in clinical stage), Bristol Myers Squibb, GSK, and Roche, with over 40 clinical-stage assets and 170 partnered assets advancing through development.

Differentiator

Problem solved

Functional benefit

Products and services

• OGAP-Verify Platform
• OGAP-Splice Platform
• Obrixtamig (OBT620)
• BI 3820768 (OB33)

Quantifiable outcome

• Detection sensitivity of 50 copies-per-cell surpasses IHC methods
• +1 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Four partnerships are on record, tiered core.

• Bristol Myers SquibbcoreStrategic or Co-development Partner · 9 April 2026Multi-year strategic collaboration announced April 9, 2026 to discover and develop next-generation T-cell engager therapies for solid tumors. OBT leverages its OGAP-Verify platform to identify novel tumor-selective targets and generate therapeutic candidates. BMS leads subsequent research, development, and commercialization. OBT receives upfront payment plus potential milestone payments and royalties.
• GSKcoreStrategic or Co-development Partner · 10 December 2025Multi-year strategic research collaboration announced December 10, 2025 to identify new molecular targets for antibody-based cancer therapies using OBT's OGAP-Verify proteomics platform. OBT receives undisclosed upfront payment plus potential milestone payments and royalties. GSK assumes responsibility for downstream research, development, and commercialization.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 1 January 2013Long-standing partnership initiated in 2013 and expanded in 2020 and 2023. Collaboration has generated multiple development-stage assets including three clinical programmes (obrixtamig, BI 3820768/OB33) and a fourth target optioned in January 2025. Obrixtamig (DLL3/CD3 T-cell engager) has advanced to global Phase III trials (DAREON-Lung-1, DAREON-NEC-1) for extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinoma.
• RochecoreStrategic or Co-development PartnerActive collaboration with Roche on antibody-based therapeutics development, leveraging OBT's target discovery capabilities.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Zymeworks: Clinical-stage biotech developing multifunctional biotherapeutics including bispecific antibodies and ADCs. Comparable therapeutic modality focus (bispecifics, ADCs) and partnership-driven development model. Both companies license platform technology and partnered assets to larger pharma.
• AbCellera Biologics: Clinical-stage antibody discovery platform company that partners with pharma to discover and develop therapeutic antibodies using its proprietary single-cell screening technology. Highly comparable partnership-first business model and antibody discovery focus, though OBT's proteomics approach differs from AbCellera's B-cell screening platform.
• Janux Therapeutics: Clinical-stage oncology biotech developing T-cell engager (TCE) therapies using proprietary tumor-activated T-cell engager (TRACTr) technology. Overlapping TCE modality focus with OBT (e.g., obrixtamig DLL3/CD3), and comparable partnership-validation approach to advancing solid tumor therapeutics.
• Adagene: Clinical-stage biotech developing antibody-based therapeutics using its proprietary AI-powered Dynamic Precision Therapeutics platform. Comparable antibody-discovery platform model with Big Pharma collaborations (e.g., Roche, Sanofi), targeting oncology with similar partnership economics.
• Harpoon Therapeutics (acquired by Merck): Was a clinical-stage immuno-oncology company developing T-cell engagers based on its proprietary TriTAC platform for solid tumors. Recently acquired by Merck for approximately $680M, representing a relevant strategic exit comparable to OBT's TCE pipeline (e.g., obrixtamig) and validating Big Pharma demand for TCE assets.
• Xencor: Clinical-stage biotech engineering bispecific antibodies and cytokines using its proprietary XmAb platform. Directly comparable bispecific antibody engineering focus and partnership-first business model with multiple pharma collaborators advancing XmAb-derived candidates.
• MacroGenics: Clinical-stage oncology biotech developing antibody-based therapeutics including bispecifics (e.g., DART and TRIDENT platforms) and ADCs. Comparable focus on bispecific antibodies for oncology with multiple partnered programs with major pharma.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs), combining antibody targeting with immune stimulation. Comparable ADC-adjacent modality and partnership validation approach for next-generation oncology biologics.
• Compugen: Clinical-stage cancer immunotherapy company using computational biology to identify novel drug targets and develop antibody-based therapeutics. Comparable target-discovery approach for immuno-oncology and partnership-driven development model (e.g., AstraZeneca collaboration).

Broad incumbents

• Regeneron: Large established biopharma with its proprietary VelocImmune antibody discovery platform and multiple internal antibody-based oncology programs (e.g., Linvoseltamab bispecific). Operates broadly across the same antibody therapeutics space as OBT but at much larger scale with full integrated capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/oxford-biotherapeutics-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds11 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford BioTherapeutics